Trials / Completed
CompletedNCT00551954
Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Endothelial dysfunction (ED) has been suggested as a possible causal link between postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent trials demonstrated a reduction of cardiovascular events by treatment with the alpha glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions. We were interested whether patients with newly diagnosed type 2 diabetes showed postprandial ED and if so whether acarbose was able to improve this condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acarbose | 100 mg (tablets) t.i.d. |
| DRUG | placebo | one tablet t.i.d. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-07-01
- First posted
- 2007-11-01
- Last updated
- 2013-03-01
Source: ClinicalTrials.gov record NCT00551954. Inclusion in this directory is not an endorsement.